NTRA / Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting

Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its ca more_horizontal

Natera beat consensus revenue and earnings estimates for the second quarter. The company also raised its full-year revenue guidance. more_horizontal

Natera (NTRA) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $1.50 more_horizontal

Natera, Inc. (NASDAQ:NTRA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Mich more_horizontal

Natera (NTRA) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.45 more_horizontal

Cutting the cash burn and other operational expenses should bring back Natera, Inc. financial health. Natera produced in 2022 loads of peer-reviewed a more_horizontal

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Natera stock broke definitively above its 200-day line Thursday after Medicare opted to reimburse for its breast cancer test. The post Why Natera Stoc more_horizontal